Precision BioSciences, Inc. DTIL
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- +67.07%
- 1 year
- -14.83%
- Open
- 7.06
- Prev close
- 7.06
- Mkt cap
- 191.83M
- Vol
- 167.79K
- Avg vol
- 256.27K
- EPS
- -1.35
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.82
- High
- 7.42
- Forward P/E
- -0.66
- Beta
- 1.69
- Short ratio
- 2.42
- Inst. own
- 44.70%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 1, 2024
- 50-d avg
- 7.35
- 200-d avg
- 9.90
- 1y target
- 33.60
5D chart
Signals (81)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 2, 3:45 PM | 9 hours ago |
| MACD: Sell Signal | Nov 2, 3:40 PM | 9 hours ago |
| SMA: Bullish | Nov 2, 3:20 PM | 9 hours ago |
| SMA: Bullish | Nov 2, 3:10 PM | 9 hours ago |
| SMA: Bearish | Nov 2, 3:05 PM | 9 hours ago |
| SMA: Bearish | Nov 2, 3:05 PM | 9 hours ago |
| SMA: Bullish | Nov 2, 2:25 PM | 10 hours ago |
| MACD: Buy Signal | Nov 2, 2:25 PM | 10 hours ago |
| SMA: Bearish | Nov 2, 2:20 PM | 10 hours ago |
| SMA: Bullish | Nov 2, 2:10 PM | 10 hours ago |
| SMA: Bearish | Nov 2, 12:10 PM | 12 hours ago |
| MACD: Sell Signal | Nov 2, 12:10 PM | 12 hours ago |
| SMA: Bearish | Nov 2, 12:00 PM | 12 hours ago |
| MACD: Buy Signal | Nov 2, 11:40 AM | 13 hours ago |
| SMA: Bullish | Nov 2, 11:35 AM | 13 hours ago |
| MACD: Sell Signal | Nov 2, 10:50 AM | 14 hours ago |
| SMA: Bearish | Nov 2, 10:40 AM | 14 hours ago |
| SMA: Bullish | Nov 2, 9:55 AM | 15 hours ago |
| SMA: Bearish | Nov 2, 9:45 AM | 15 hours ago |
| SMA: Bullish | Nov 2, 9:40 AM | 15 hours ago |
Newest 20 of 81.
News
4 days ago businesswire.com
Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
6 days ago defenseworld.net
Precision BioSciences (NASDAQ:DTIL) Stock Price Breaks Below 200 Day Moving Average – Time to Sell?
Precision BioSciences, Inc. (NASDAQ: DTIL - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of…
3 weeks ago businesswire.com
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
-
2 months ago benzinga.com
iECURE Says Updated OTC-HOPE Low-Dose Data Showed 74% Reduction In Annualized Hyperammonemic Crises, 57% Reduction In Hyperammonemic Events; Completes Phase 1/2 Dosing Across All Three Cohorts
iECURE, a private clinical-stage genome editing company, reported preliminary safety observations from all nine participants dosed with ECUR-506 across the low-, intermediate- and high-dose cohorts,…
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 35.9% to $7.3 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.2 million. Biodexa…
-
2 months ago benzinga.com
Precision BioSciences Doses First Patient In The Phase 1/2 Function-DMD Clinical Trial Evaluating PBGENE-DMD For Treatment Of Duchenne Muscular Dystrophy
PBGENE-DMD is Precision's wholly owned in vivo gene editing program designed to durably improve function. This novel approach, aiming to restore near full-length dystrophin, is applicable for up to…
2 months ago businesswire.com
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
2 months ago seekingalpha.com
Precision BioSciences: Promising HBV Editing Evidence
PBGENE-HBV's liver biopsy data provides unusually direct evidence that ARCUS is editing the viral reservoir in patients. Durable off-treatment viral control remains unproven, making the next…
2 months ago gurufocus.com
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUSÂ platform to develop in vivo gene editi
2 months ago businesswire.com
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
-
3 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $60 price target.
3 months ago businesswire.com
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
-
3 months ago benzinga.com
Precision BioSciences Promotes Alex Kelly To COO And Naresh Tanna To CFO, Effective August 1, 2026
– Leadership updates come as Precision advances its lead programs, PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy –Precision BioSciences, Inc. (NASDAQ:DTIL), a…
3 months ago businesswire.com
Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
3 months ago businesswire.com
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
-
3 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $60 price target.
3 months ago zacks.com
Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength?
Precision BioSciences (DTIL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further…
-
4 months ago benzinga.com
Precision Biosciences Activates Second Clinical Site At Washington University School Of Medicine As It Begins The FUNCTION-DMD Clinical Trial Evaluating PBGENE-DMD For Duchenne Muscular Dystrophy; Initial Safety Data Targeted For End-2026
Also in its updated corporate deck, the Company announced activation of a second clinical site at Washington University School of Medicine in St. Louis, Missouri as it commences the FUNCTION-DMD…
4 months ago gurufocus.com
Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUSÂ platform to develop in vivo gene edit
4 months ago businesswire.com
Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
-
4 months ago benzinga.com
Oppenheimer Initiates Coverage On Precision BioSciences with Outperform Rating, Announces Price Target of $20
Oppenheimer analyst Joseph Thome initiates coverage on Precision BioSciences (NASDAQ:DTIL) with a Outperform rating and announces Price Target of $20.
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $60 price target.
5 months ago benzinga.com
Why Is Precision BioSciences Stock Gaining Wednesday?
Precision BioSciences (DTIL) trades up 10.55% premarket. Bullish moving averages and new data point to strong momentum.
-
5 months ago benzinga.com
Precision BioSciences Reports PBGENE-HBV Achieves 100% pgRNA Loss And 10-Fold cccDNA Transcript Reduction In ELIMINATE-B Study
- New biopsy data demonstrate thatPBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts -- In the <1% of cccDNA…
5 months ago gurufocus.com
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUSÂ platform to develop in vivo gene edit
5 months ago businesswire.com
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
-
5 months ago benzinga.com
Precision BioSciences Announces Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need…
5 months ago businesswire.com
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
-
5 months ago benzinga.com
Precision BioSciences Announces New Preclinical Data From PBGENE-DMD Program In Oral Presentation At ASGCT 2026 Annual Meeting
– New preclinical data show PBGENE-DMD drove up to a 3x higher dystrophin protein restoration in skeletal muscle and up to 12x higher in respiratory muscle in early-juvenile mice compared to…
5 months ago businesswire.com
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
6 months ago zacks.com
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates
Precision BioSciences (DTIL) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $2.21 per share a year ago.
-
6 months ago benzinga.com
Precision BioSciences Q1 EPS $(0.75) Misses $(0.66) Estimate, Sales $10.838M Beat $4.050M Estimate
Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.66) by 15.38 percent. This is a 66.06 percent increase over…
6 months ago businesswire.com
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
6 months ago businesswire.com
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
-
6 months ago benzinga.com
Precision Biosciences Starts Phase 1/2 FUNCTION-DMD Study Of PBGENE-DMD, In Vivo Gene Editing Treatment For Duchenne Muscular Dystrophy
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need…
-
6 months ago benzinga.com
iECURE To Present Clinical Data From Ongoing ECUR-506 Trial Using Precision Bioscience's ARCUS Nuclease At American Society Of Gene & Cell Therapy Annual Meeting May 11-15
iECURE has licensed the ARCUS® nuclease from Precision BioSciences for four gene insertion programs including OTC, CTLN1 and PKU.The poster presentation at SIMD will feature one-year post-treatment…
-
6 months ago benzinga.com
Jones Trading Assumes Precision BioSciences at Buy, Announces Price Target of $30
Jones Trading analyst Catherine Novack assumes Precision BioSciences (NASDAQ:DTIL) with a Buy rating and announces Price Target of $30.
-
6 months ago benzinga.com
Precision BioSciences Receives Clinical Trial Application Approval To Expand Ongoing Global ELIMINATE-B Clinical Trial Of PBGENE-HBV
- France and Romania planned for inclusion in the global ELIMINATE-B trial supporting broader patient enrollment -Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company…
-
7 months ago benzinga.com
Earnings Scheduled For March 12, 2026
Earnings Scheduled For March 12, 2026
-
7 months ago benzinga.com
Precision BioSciences Receives Two Notices Of Allowance From USPTO For Patent Applications Relating To PBGENE-HBV Program
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need…
-
7 months ago benzinga.com
Precision BioSciences Says FDA Grants Fast Track Designation To PBGENE-DMD For Treatment Of Duchenne Muscular Dystrophy
– Fast Track designation aims to facilitate development and expedite review of drugs, such as PBGENE-DMD to treat serious conditions like Duchenne muscular dystrophy –– March 17, 2026 virtual webinar…
-
8 months ago benzinga.com
Precision BioSciences Lands $7.5M Milestone Payment From TG Therapeutics In MS Drug Trial
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need…
-
8 months ago benzinga.com
Precision BioSciences Receives Study May Proceed Notification From FDA, Allowing Co To Initiate IRB Activities And Clinical Trial Site Activation For FUNCTION-DMD Phase 1/2 Clinical Trial For PBGENE-DMD
– U.S. FDA Study May Proceed notification enables initiation of clinical trial site activation for the FUNCTION-DMD Phase 1/2 clinical study in patients with Duchenne muscular dystrophy (DMD) ––…
-
9 months ago benzinga.com
Precision BioSciences Provides 2026 Business Update Emphasizing Progress In PBGENE-HBV And PBGENE-DMD Programs, Anticipated Clinical Data In 2026, And Strong $137M Cash Runway
Phase 1/2a ELIMINATE-B trial for PBGENE-HBV ongoing across multiple dosing cohorts; Data updates expected at medical conferences in 2026PBGENE-DMD expecting IND clearance in Q1 2026 for Phase 1/2…
-
9 months ago benzinga.com
Precision Biosciences Advances Gene Therapy Pipeline With Ongoing Phase 1/2a ELIMINATE‑B Trial For PBGENE‑HBV And Anticipated Q1 2026 IND Clearance For PBGENE‑DMD; Data Updates Expected Throughout 2026
Phase 1/2a ELIMINATE-B trial for PBGENE-HBV ongoing across multiple dosing cohorts; Data updates expected at medical conferences in 2026PBGENE-DMD expecting IND clearance in Q1 2026 for Phase 1/2…
-
9 months ago benzinga.com
Precision BioSciences Partner iECURE Secures FDA Alignment Toward BLA, RMAT Designation, And UK ILAP Innovation Passport For ECUR-506 In Neonatal OTC Deficiency
Reached alignment with FDA on endpoints, comparators and sample size for the ongoing OTC-HOPE study which could support Biologics License Application (BLA)Awarded Innovation Passport under the United…
-
11 months ago benzinga.com
Precision BioSciences to Present Gene Editing Therapy for Chronic Hepatitis B at Hep-DART 2025
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need…
-
11 months ago benzinga.com
Precision BioSciences Announces ~$75M Underwritten Offering Of 10.815M Shares And Accompanying Warrants To Purchase Up To 5,407,500 Shares Of Common Stock At A Combined Price Of $6.14
Precision BioSciences, Inc. (NASDAQ:DTIL) ("Precision"), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet…